Morgan Stanley Rates Pharvaris (PHVS) buy, $46 Price Target
Morgan Stanley maintains its buy rating on Pharvaris N.V. with a $46 price target, a 32.53% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Morgan Stanley rated Pharvaris N.V. ($PHVS) "buy" with a $46 price target on June 25, 2026.
Since the rating, $PHVS is up 1.7% after 1 week, up 2.0% after 1 month and down 16.7% to date (from the $33.30 close on Jun 25, 2026).
PHVS
Pharvaris N.V.
Key Points
- Morgan Stanley reiterated its buy rating on Pharvaris N.V. (PHVS) with a price target of $46 on June 25, 2026.
- Morgan Stanley's $46 price target implies 32.53% upside from Pharvaris N.V.'s ($PHVS) current $34.71 share price.
- Shares of Pharvaris traded at $33.29 on Friday, with a market cap of about $2.33 billion and a forward P/E ratio indicating it's not yet profitable.
- Insiders at Pharvaris, including the CEO and Chief Medical Officer, have been active, with recent transactions reported in June 2026.
Get $PHVS trade alerts by text
We text you when insiders, Congress or big funds trade $PHVS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Pharvaris N.V. alert may contain errors. Disclosures
Morgan Stanley has reiterated its buy rating on Pharvaris N.V. (PHVS) with a price target of $46 as of June 25, 2026. The analyst behind this reaffirmation is Matthew Harrison. Shares of Pharvaris were trading at $33.29 on Friday.
Morgan Stanley vs. the S&P 500
Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.
Pharvaris N.V. Stock Down 4.6%
Shares of NasdaqGS:PHVS traded near $33.29 on Friday. Pharvaris N.V. has a market cap of approximately $2.33 billion. The company is not yet profitable, reflected in its negative forward P/E ratio of -12.65. The stock has a 52-week low of $16.72 and a high of $35.33. It has a 50-day moving average of $30.41 and a 200-day moving average of $26.65. Pharvaris also maintains a strong financial position with a current ratio of 11.24 and a quick ratio of 10.99.
$PHVS price target
Pharvaris N.V. daily closes and this analyst's $46 target. Not advice.
Insider Buying and Selling at Pharvaris N.V.
Insider activity at Pharvaris N.V. shows significant movement. On June 18, 2026, Chief Medical Officer Lu Peng sold 300 shares at an average price of $34.00 under a planned transaction. On the same day, Lu Peng also bought 300 shares at $2.59 in an unplanned move. Additionally, CEO Berndt Modig executed a planned sale of 2,291 shares at $31.07 on June 15, 2026.
Analysts Set New Price Targets
On June 25, 2026, Morgan Stanley maintained its buy rating on Pharvaris N.V. with a $46 price target. Other analysts have also shown optimism. Citizens maintained a buy rating with a $74 target on May 13, 2026, while Wolfe Research initiated coverage with a buy rating and a $42 target on April 9, 2026. The consensus among analysts is a strong buy, with an average target price of $46.09 based on 13 analyst opinions.
About Pharvaris N.V.
Pharvaris N.V. is a late-stage biopharmaceutical company headquartered in Zug, Switzerland. It focuses on developing and commercializing therapies for rare diseases, particularly those involving bradykinin-mediated angioedema. The company's lead product, deucrictibant, is in phase 3 trials for treating hereditary angioedema (HAE) and other related conditions. Pharvaris was founded in 2015 and is led by CEO Berndt Modig.
Bottom Line
Morgan Stanley's reaffirmation of its buy rating on Pharvaris N.V. highlights continued confidence in the company's potential. With shares trading at $33.29, the stock reflects a robust market interest, though it remains unprofitable. Insider transactions and analyst ratings provide valuable insights into the company's strategic direction and market perception.
Related Filing Alerts
Source: Morgan Stanley's rating change on $PHVS (Jun 25, 2026). Written by software, not financial advice. How we make alerts